Aminoglycoside adaptive resistance: importance for effective dosage regimens.
about
Insights into Newer Antimicrobial Agents Against Gram-negative BacteriaPhenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populationsPharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyBreakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis.Extended-interval gentamicin dosing in achieving therapeutic concentrations in malaysian neonatesLow-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View.Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates.Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.Estimating drug-free period using a graphical method: an alternative way to monitor extended-interval dosing of gentamicin therapy.MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides.Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants.Stochastic process pharmacodynamics: dose timing in neonatal gentamicin therapy as an example.Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis.Conditional probability analysis of multidrug resistance in Gram-negative bacilli isolated from tertiary medical institutions in South Korea during 1999-2009.We Give Aminoglycoside Antibiotics at the End of Hemodialysis.
P2860
Q26751255-37B9878C-5C20-428C-B1CC-00E80F1F5853Q33722011-EDE487FD-E2FD-43CC-8A00-73806FB0338CQ33827819-20F59787-47BA-4C5B-A4F0-99B68F9F7DB2Q34042263-E3A4216A-A43B-4A62-A7C5-45D9F3426126Q34570930-D52A835D-ACFF-461B-8F1E-B65FA1685248Q35297198-D13A733A-A3F4-4134-819B-2DBAF013219AQ35566356-09C6AD1A-7020-4D40-A549-5545B72B015AQ35758962-C45AA3F5-0B76-4554-979E-54D979AC78EEQ37568933-F6C9CA89-542C-498F-9543-E9BB50F3A362Q38693212-4D579261-9224-4AA6-B101-582AA0B06791Q38696468-F5FBF34D-4838-4A59-AF4D-9EEE3EE1C848Q38823748-8C8AA7E4-46A3-4D04-A153-6BD141700A5DQ39015529-E47ABCD3-51DD-40B1-BF1B-6782C5222D70Q39743310-75A56FD6-FF47-4403-A7A9-EF1ED3EA6308Q40326667-CF74FA6D-4BB5-4A20-8FF1-1ACBF12FD47AQ41494950-CA74C055-1FF3-466C-929B-4C9CA29BBB03Q42717931-99FA17FA-4B67-4123-963B-BFBF2F2C7C37Q51930719-22F247E3-E396-4FA2-B407-31E24FF14707Q53802828-D7325721-4C8F-47FF-877C-A911B65ECC50Q54675401-58D497F6-C4DF-4178-B63A-D746DAFC9692
P2860
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
@ast
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
@en
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
@nl
type
label
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
@ast
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
@en
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
@nl
prefLabel
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
@ast
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
@en
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
@nl
P1433
P1476
Aminoglycoside adaptive resistance: importance for effective dosage regimens.
@en
P2093
P304
P356
10.2165/00003495-200161060-00001
P577
2001-01-01T00:00:00Z
P6179
1046364964